
JoAnn Lindenfeld, MD, FACC, FAHA, FHFSA

JoAnn Lindenfeld, M.D is Professor of Medicine and the Director of Heart Failure and Heart Transplantation Section at Vanderbilt Heart and Vascular Institute. Dr.Lindenfeld founded the Heart Failure and Transplantation program at the University of Colorado where she also co-founded the Center for Women's Health Research-the largest center focused on cardiometabolic disease in women. Dr. Lindenfeld is Past President of the Heart Failure Society of America. She serves as Deputy Editor of the *Journal of the American College of Cardiology: Heart Failure* and as a Senior Editor of the *Journal of the International Society of Heart and Lung Transplantation* as well as on the editorial boards of the *Journal of the American College of Cardiology* and the *Journal of Cardiac Failure*. Dr. Lindenfeld served as the chairman of the Heart Failure Society Clinical Practice Guidelines Committee for the 2006 and 2010 guidelines and is currently a member of the AHA/ACC/HFSA Heart Failure Guideline Writing Committee.

Dr. Lindenfeld is a Fellow of the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America. She was a member of the Cardiorenal Advisory Panel of the Food and Drug Administration (FDA) for 8 years and was also a member of the FDA Advisory Panel on Circulatory Devices and is currently an ad hoc adviser to that panel.

Dr. Lindenfeld has been an investigator in a large number of clinical trial and has served on multiple Steering Committees, End Point Committees and Data and Safety Monitoring Committees including COAPT, BEAT-HF, FIX-HF 5C, EMPEROR-Preserved and EMPEROR-Reduced and is the Chair of the Guide HF Trial. She is the author of a more than 300 original papers, reviews, and book chapters in the field of heart failure and heart transplantation

Dr. Lindenfeld has had a long interest in women's health and was the first to suggest that women are more likely than men to have heart failure with preserved ejection fraction. More recently Dr. Lindenfeld has pioneered the use of Hepatitis C positive organ donors which has significantly expanded the donor pool for solid organ transplant recipients. She has discovered that continuous flow mechanical circulatory support significantly affects vascular remodeling—both large vessels such as the aorta and medium size vessels such as the coronary arteries. In addition Dr. Lindenfeld has pioneered the use of urinary sodium as a biomarker to assess patients at risk or worsening heart failure.